Acute Myeloid Leukemia

An aggressive hematologic malignancy of myeloid progenitor cells, primarily affecting older adults and treated with molecularly stratified induction, consolidation, maintenance, and relapse regimens.

Phase 1/2 and later readouts in Acute Myeloid Leukemia, in your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

Coverage in progress. AssetMemo has not yet run its full census for Relapsed/Refractory Acute Myeloid Leukemia, so the assets listed for it are not complete.

Combined attributable cost

$4.5B+

Drug spend

Not yet sourced

How this is calculated ↗

Sum of 2 indications below.

All assets in Acute Myeloid Leukemia

← Oncology